Cart
sales@molnova.com
Soticlestat
CAS No. 1429505-03-2
Soticlestat ( OV935; TAK-935 )
Catalog No. M23591 CAS No. 1429505-03-2
Soticlestat is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 132 | In Stock |
|
| 10MG | 215 | In Stock |
|
| 25MG | 430 | In Stock |
|
| 50MG | 619 | In Stock |
|
| 100MG | 896 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSoticlestat
-
NoteResearch use only, not for human use.
-
Brief DescriptionSoticlestat is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor.
-
DescriptionSoticlestat is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. It has the potential for epilepsy syndromes research.
-
SynonymsOV935; TAK-935
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
RecptorCYP46A1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1429505-03-2
-
Formula Weight373.5
-
Molecular FormulaC23H23N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (267.77 mM; Need ultrasonic)
-
SMILESC1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Toshiya Nishi, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020 Oct 13;10(1):17081.
molnova catalog
related products
-
1-Ethynylpyrene
1-Ethynylpyrene is an aryl acetylenic inhibitor of CYTP450 1A1(IC50=0.18 μM), 1A2(IC50 = 0.32 μM), and 2B1(IC50 = 0.04 μM).
-
7-Hydroxyflavone
7-Hydroxyflavone is a potent inhibitor of CYP1A1 with a Ki value of 0.015 μM and exhibits 6-fold greater selectivity for CYP1A1 over CYP1A2.with anti-inflammatory activity.
-
Harman hydrochloride
Harman hydrochloride can directly induce CYP1A1 gene expression in an AhR-dependent manner and may represent a novel mechanism by which harman promotes mutagenicity, co-mutagenicity and carcinogenicity.
